Blog
RSS FeedPosted by Michael Wonder on 29 Mar 2018
Shire reports regulatory milestones for investigational hereditary angioedema treatment lanadelumab
29 March 2018 - Filings are supported by data from HELP, the pivotal Phase 3 efficacy and safety study. ...
Posted by Michael Wonder on 27 Mar 2018
Valeant Canada announces Health Canada approval of Contrave extended-release tablets for chronic weight management in adults
26 March 2018 - Valeant Canada today announced that Health Canada has approved Contrave extended-release tablets for use as an adjunct ...
Posted by Michael Wonder on 26 Mar 2018
Health Canada accepts Cardiome's Xydalba new drug submission and grants priority review
22 March 2018 - Approval decision expected in third quarter 2018. ...
Posted by Michael Wonder on 23 Mar 2018
Health Canada approves Rituxan subcutaneous formulation for Canadians with chronic lymphocytic leukaemia
22 March 2018 - Rituxan SC is a new treatment option for Canadians living with one of the most common forms ...
Posted by Michael Wonder on 21 Mar 2018
BMS withdraws submission for Opdivo for urothelial carcinoma
20 March 2018 - Health Canada's handling of the submission is perplexing. ...
Posted by Michael Wonder on 16 Mar 2018
Ipsen announces Health Canada approval of Dysport Therapeutic (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults
15 March 2018 - With this approval, Dysport Therapeutic now has the broadest label of all approved botulinum neurotoxins for spasticity, ...
Posted by Michael Wonder on 14 Mar 2018
Valeant receives Health Canada approval of Siliq (brodalumab) for moderate-to-severe plaque psoriasis
14 March 2018 - Valeant Canada announced that Health Canada granted on 6 March the Notice of Compliance for Siliq (brodalumab) ...
Posted by Michael Wonder on 07 Mar 2018
Trumenba (meningococcal Group B vaccine) now available in Canada
6 March 2018 - Trumenba is the only vaccine indicated for adolescents and young adults aged 18 to 25 to prevent ...
Posted by Michael Wonder on 07 Mar 2018
Health Canada approves Lonsurf (trifluridine/tipiracil) for metastatic colorectal cancer
6 March 2018 - Lonsurf, a new important treatment option for adult patients with metastatic colorectal cancer that has been shown ...
Posted by Michael Wonder on 27 Feb 2018
Health Canada has approved Fasenra (benralizumab injection) for patients with severe eosinophilic asthma
26 February 2018 - AstraZeneca Canada today announced that Health Canada has approved Fasenra (benralizumab injection) as an add-on maintenance treatment ...
Posted by Michael Wonder on 23 Feb 2018
Health Canada approves Bavencio (avelumab for injection) for the treatment of metastatic Merkel cell carcinoma in previously treated adult patients
22 February 2018 - First Health Canada approved treatment for rare and aggressive type of skin cancer. ...
Posted by Michael Wonder on 16 Feb 2018
Health Canada approves new indication for Zytiga (abiraterone acetate), broadening its use for treatment of newly diagnosed metastatic prostate cancer
15 February 2018 - Zytiga, used in combination with prednisone and androgen deprivation therapy, was shown to reduce the risk ...
Posted by Michael Wonder on 16 Feb 2018
Health Canada approves Ocrevus (ocrelizumab) for Canadians living with primary progressive multiple sclerosis
15 February 2018 - Ocrevus is a new treatment for a rare and worsening form of MS that impacts 10-15% ...
Posted by Michael Wonder on 14 Feb 2018
Health Canada approves Ipsen's Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours
13 February 2018 - Somatuline Autogel is the first and only somatostatin analog approved in Canada to treat enteropancreatic neuroendocrine ...
Posted by Michael Wonder on 04 Feb 2018
Tagrisso (osimertinib) receives full Health Canada approval for targeted treatment of non-small-cell lung cancer
31 January 2018 - Approval based on Phase III AURA3 trial that demonstrated significant improvement in progression-free survival with Tagrisso compared ...